|1.||Nishizawa, Yoshiki: 4 articles (01/2014 - 01/2004)|
|2.||Inaba, Masaaki: 4 articles (01/2014 - 01/2004)|
|3.||Ishimura, Eiji: 3 articles (01/2014 - 05/2005)|
|4.||Okuno, Senji: 3 articles (01/2014 - 05/2005)|
|5.||Yamakawa, Tomoyuki: 3 articles (01/2014 - 05/2005)|
|6.||Khosla, Sundeep: 3 articles (11/2010 - 04/2003)|
|7.||Stepan, Jan J: 2 articles (08/2013 - 04/2009)|
|8.||Silverman, S: 2 articles (10/2012 - 02/2011)|
|9.||Storer, Norma: 2 articles (07/2012 - 01/2011)|
|10.||Brown, Todd T: 2 articles (07/2012 - 01/2011)|
05/01/2015 - "Plasma C-terminal telopeptide of type I collagen (CTX) is the nominated reference bone resorption marker. "
11/01/2014 - "The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. "
03/01/2012 - "Serum C-terminal telopeptide of type I collagen (sCTX, a bone-resorption marker) decreased by 61%, 75% and 73% in the 12.5, 25 and 50 mg dose groups, respectively. "
05/01/2010 - "A negative correlation of serum C-terminal telopeptide of type I collagen (telopeptide-C) was observed with bone mass density (BMD) in postmenopausal control (r = -0.70, p < 0.05) and osteoporotic females (r = -0.46, p < 0.05) indicating increased bone resorption in these subjects. "
01/01/2008 - "For example, a decrease of more than 30% in the serum concentration of CTX (C-terminal telopeptide of type I collagen) will be regarded as a significant change indicating that treatment has reduced bone resorption."
02/01/2002 - "Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis."
03/01/2015 - "A population pharmacodynamic model was constructed by the urinary C-terminal telopeptide of type I collagen (uCTx) and the lumbar spine bone mineral density (BMD) data obtained in clinical studies, including a phase II study of Japanese osteoporosis patients treated with ibandronate for 6 months. "
02/01/2011 - "The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies. "
01/01/2015 - "Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosis."
01/01/2014 - "Bone formation marker procollagen I N-terminal peptide (PINP) and resorption marker C-terminal telopeptide of type I collagen (β-CTX) are useful biomarkers for differential diagnosis and therapeutic evaluation of osteoporosis, but reference values are required. "
01/01/2011 - "This was a longitudinal observational study comparing levels of bone turnover markers (C-terminal telopeptide of type I collagen [CTX] and osteocalcin [OC]), OPG, sRANKL and inflammatory cytokines (soluble tumour necrosis factor [TNF]-α receptor [sTNFR]-I, sTNFR-II and interleukin-6) prior to ART and 6-12 months after ART initiation with a TDF- versus non-TDF-containing regimen in HIV-infected subjects 18-50 years old. "
05/01/2014 - "A cross sectional study examining correlations between BMD (Duel-energy X ray absorptiometry; (DXA) and dietary intake (3-day diaries), body composition and plasma bone and inflammatory markers: C-terminal telopeptide of type I collagen (CTX) and procollagen type I N propeptide (P1NP), C- reactive protein (CRP), interleukin 6 and 10 (IL-6, IL-10), tumour necrosis factor (TNF) and osteoprotegerin (OPG). "
01/01/2007 - "It was the aim of this study to investigate parameters of bone turnover such as serum bone-specific alkaline phosphatase (BALP) and N-terminal midfragment of osteocalcin (N-MID), as well as serum C-terminal telopeptide of type I collagen (CTX) in patients with primary bone tumors and to investigate their validity in differentiating malignant from benign bone tumors. "
07/01/1994 - "The present study was performed to evaluate whether information concerning synthesis and degradation of type I collagen in multiple myeloma (MM) as obtained by serum analyses of C-terminal propeptide of type I procollagen (PICP) and the C-terminal telopeptide of type I collagen (ICTP) may be useful in evaluating the development of osteolytic bone destruction. "
|2.||Collagen Type I (Type I Collagen)
|4.||ibandronic acid (Boniva)
|5.||Biological Markers (Surrogate Marker)
|6.||procollagen type I carboxy terminal peptide (PICP)
|7.||Parathyroid Hormone (Parathormone)
|8.||Interleukin-6 (Interleukin 6)
|9.||ruberythric acid (AlP)
|1.||Renal Dialysis (Hemodialysis)